Oncolytics Biotech Inc (NAS:ONCY)
$ 1.07 0 (0%) Market Cap: 82.02 Mil Enterprise Value: 64.91 Mil PE Ratio: 0 PB Ratio: 6.22 GF Score: 37/100
Back to the Transcripts List

Q2 2024 Oncolytics Biotech Inc Earnings Call Transcript

Aug 01, 2024 / 08:30PM GMT
Release Date Price: $1.03 (-0.96%)

Key Points

Positve
  • Oncolytics Biotech Inc (ONCY) held a productive Type C meeting with the FDA, aligning on key elements for the next steps in breast cancer treatment.
  • The company reported strong tumor response and progression-free survival results from the BRACELET-1 study.
  • Oncolytics Biotech Inc (ONCY) dosed the first patient in the modified FOLFIRINOX cohort of the GOBLET study, indicating progress in pancreatic cancer treatment.
  • The company entered into a collaboration with the Global Coalition for Adaptive Research (GCAR) for an adaptive registration-enabling pancreatic cancer trial.
  • Oncolytics Biotech Inc (ONCY) reported a cash runway into 2025, indicating financial stability to reach critical milestones.
Negative
  • The CEO, Matt Coffey, is currently on medical leave, which may impact leadership continuity.
  • The company faces risks associated with intellectual property production and regulatory actions.
  • Overall survival results from the BRACELET-1 trial are still pending, creating uncertainty.
  • The company reported a net loss of $7.3 million for the second quarter of 2024.
  • There is ongoing competition in the breast cancer treatment market, particularly from antibody-drug conjugates (ADCs).
Operator

Good afternoon, and welcome to Oncolytics Biotech second-quarter 2024 conference call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to Jon Patton, Director of Investor Relations and Communication. Please go ahead.

Jon Patton
Oncolytics Biotech Inc - Director of Investor Relations and Communication

Thank you, operator. Earlier today, Oncolytics issued a press release providing recent operational highlights and financial results for the second quarter of 2024. A replay of today's call will be available on the Events section of the Oncolytics website. And after remarks from company management, we will open the call for Q&A.

As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects and the development and commercialization of pelareorep, including statements regarding the company's mission, strategy and milestones, the company's belief as of the potential and

Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.